A Study to Evaluate EDG-7500 in People With Renal Impairment

Summary

The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of kidney function impairment versus participants with normal kidney function. The safety of EDG-7500 in participants with different levels of kidney function impairment will also be evaluated in this study.

Timeline

Start

2025-07-22

Primary completion

2025-12-22

Completion

2025-12-26

Drugs

Indications